256 related articles for article (PubMed ID: 18326949)
1. Monotherapy vs combination therapy for dyslipidemia in the elderly.
Shepherd J
Am J Geriatr Cardiol; 2008; 17(2):108-13. PubMed ID: 18326949
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
5. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
6. Colesevelam hydrochloride in the management of dyslipidemia.
Armani A; Toth PP
Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
[TBL] [Abstract][Full Text] [Related]
8. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
[TBL] [Abstract][Full Text] [Related]
9. Treating dyslipidemia in the high-risk patient.
Jones PH
J Fam Pract; 2010 Feb; 59(2):E1. PubMed ID: 20141719
[TBL] [Abstract][Full Text] [Related]
10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
12. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Zubaid M; Shakir DK; Bazargani N; Binbrek A; Gopal R; Al-Tamimi O; Bakir S
J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
[TBL] [Abstract][Full Text] [Related]
13. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
Ballantyne CM
Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
[TBL] [Abstract][Full Text] [Related]
14. Treatment of high-risk older persons with lipid-lowering drug therapy.
Aronow WS
Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
[TBL] [Abstract][Full Text] [Related]
15. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Mohiuddin SM; Pepine CJ; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Am Heart J; 2009 Jan; 157(1):195-203. PubMed ID: 19081418
[TBL] [Abstract][Full Text] [Related]
17. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP; Keating GM
Am J Cardiovasc Drugs; 2009; 9(6):401-9. PubMed ID: 19929038
[TBL] [Abstract][Full Text] [Related]
18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
19. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
20. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
